The licence agreement signed with Galderma back in 2014, was a supply agreement only. Part of the terms of this agreement were that "The licence agreement is terminable by either party under certain conditions including a two year notice period by the pharmaceutical company." If Galderma have not notified TFS/Quintis/Santalis of a termination in writing, wouldn't it be fair to say......"the agreement is still current."..
The fact it has not been active is not a breach. Perhaps, Galderma were quietly trying to sneak away from TFS/Quintis/Santalis, because they had found another supplier. There could be a multitude of different reasons.
- Forums
- ASX - By Stock
- QIN
- Ann: Updated forbearance agreement with Noteholders
Ann: Updated forbearance agreement with Noteholders, page-16
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)